The Business Research Company’s report on the Acute Ischemic Stroke Drugs Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the acute ischemic stroke drugs market further?
The rise in the prevalence of chronic diseases is anticipated to propel the growth of the acute ischemic stroke drug market in the coming years. Chronic diseases, also known as non-communicable diseases, refer to conditions that endure for a year or longer and necessitate continuing medical care, restrict everyday activities, or both. The primary causes of death and disability are chronic illnesses such as heart disease, cancer, and diabetes. Acute ischemic stroke drugs are primarily used in chronic diseases to reduce the chances of clot formation and strokes and restore blood flow to the brain. For instance, in September 2022, according to the reports shared by the World Health Organization (WHO), a Switzerland-based health agency, due to chronic diseases, it is estimated 41 million people die each year, which is equivalent to 74% of all deaths globally, and 17 million individuals die before the age of 70 from chronic diseases. By 2025, an estimated 164 million Americans, or nearly 49% of the population, would be living with chronic illnesses. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the acute ischemic stroke drug market.
Access Your Free Sample of the Global Acute Ischemic Stroke Drugs Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10049&type=smp
What are the key factors influencing the forecasted market size of the acute ischemic stroke drugs industry?
The acute ischemic stroke drugs market size has grown strongly in recent years. It will grow from$13.5 billion in 2024 to $14.21 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing incidence of stroke, government initiatives and healthcare policies, increased awareness and education, strategic collaborations and partnerships, aging population
The acute ischemic stroke drugs market size is expected to see strong growth in the next few years. It will grow to “$17.96 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to emerging therapies and drug pipeline, precision medicine and personalized therapies, global healthcare infrastructure development, increasing healthcare expenditure, telemedicine and remote patient monitoring. Major trends in the forecast period include advancements in thrombolytic therapies, neuroprotective agents development, personalized medicine and biomarker research, telemedicine and remote monitoring, collaborations and strategic partnerships.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10049&type=smp
Who are the leading competitors in the acute ischemic stroke drugs market?
Major companies operating in the acute ischemic stroke drugs market include F. Hoffmann-La Roche AG, C.H. Boehringer Sohn AG & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, AstraZeneca plc, ZZ Biotech LLC, NoNO Inc., Biogen Inc., Athersys Inc., Bayer AG, Sanofi S.A., Pfizer Inc., DiaMedica Therapeutics, Lumosa Therapeutics Co. Ltd., Johnson & Johnson, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals LLC, Nanjing Yoko Biomedical Co. Ltd., TrueBinding Inc., GNT Pharma Co. Ltd., aptaTargets SL, NuvOX Pharma, Simcere Pharmaceutical Co. Ltd., Genentech Inc., Pharming Technologies B.V., SanBio BV, Revalesio Corporation, Stemedica Cell Technologies Inc., CorInnova Incorporated, Phagenesis
Which emerging trends are set to transform the acute ischemic stroke drugs market landscape?
Major companies operating in the acute ischemic stroke drug market are developing innovative formulations, such as sublingual formulations of edaravone and dexborneol for acute ischemic stroke. A sublingual formulation of edaravone and dexborneol is a medication designed to be placed under the tongue for rapid absorption into the bloodstream, combining the antioxidant and anti-inflammatory effects of both compounds to enhance treatment efficacy. For instance, in October 2024, Simcere Pharmaceutical, a China-based pharmaceutical company, granted breakthrough therapy designation to Sanbexin, a sublingual formulation of edaravone and dexborneol, for treating acute ischemic stroke (AIS). This designation was based on promising results from the TASTE-SL phase 3 clinical trial (NCT04950920), where 64.4% of patients treated with Sanbexin achieved a modified Rankin Scale (mRS) score of =1 at 90 days, compared to 54.7% in the placebo group. The treatment, which can be administered outside of hospital settings, aims to reduce disability and improve outcomes in AIS patients.
How do different geographies compare in terms of market share and growth potential in the acute ischemic stroke drugs market?
North America was the largest region in the acute ischemic stroke drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global acute ischemic stroke drugs market report during the forecast period. The regions covered in the acute ischemic stroke drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report
Which major segments of the acute ischemic stroke drugs market are experiencing the fastest growth?
The acute ischemic stroke drugs market covered in this report is segmented –
1) By Type: Tablet, Capsule, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Hospitals, Diagnostic Centers, Other Applications
Subsegments:
1) By Tablet: Immediate Release Tablets, Extended Release Tablets, Orally Disintegrating Tablets
2) By Capsule: Hard Shell Capsules, Soft Gelatin Capsules, Extended Release Capsules
3) By Other Types: Injectable Solutions, Intravenous (IV) Preparations, Inhalation Formulations
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10049
What defines the structure and scope of the acute ischemic stroke drugs market?
Acute ischemic stroke drugs refer to treatment medications for a medical emergency that occurs when blood flow to the brain is interrupted, typically due to a blood clot. These drugs aim to restore blood flow to the affected part of the brain and minimize brain damage.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
